Chemotherapy of Disseminated Soft Tissue Sarcomas

  • Laurence H. Baker
Part of the Cancer Treatment and Research book series (CTAR, volume 15)


In 1972, adriamycin was introduced into clinical trial and quickly became identified as the single most important drug for the management of disseminated sarcomas. Previously, there were scattered reports in the literature indicating that different sarcomas were responsive to chemotherapeutic drugs, principally cyclophosphamide, actinomycin, and vincristine. Relatively few of these series had sufficient numbers of patients treated in a similar therapeutic regime however. Review of this early data suggests that metastatic sarcomas rarely responded 20% of the time or more. Most of those remissions were quite incomplete and short lasting and thus, of relatively little clinical benefit to the patient. Table 1 [1–6] summarizes major experiences with adriamycin as a single therapy.This data suggests that adriamycin as a single agent produces response rates of approximately 25%. The second drug whose investigation actually predated the investigation of adriamycin reported by Gottlieb et al. was DTIC (Dimethyl Trianzeno Immidazole Carboxamide). In Gottlieb’s phase II trial 17% of 53 patients treated had responded to the DTIC [7, 8].


Soft Tissue Sarcoma Synovial Sarcoma Initial Combination Therapy Metastatic Sarcoma Metastatic Soft Tissue Sarcoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    O’Bryan RM, Luce JK, Talley RW et al.: Phase II evaluation of adriamycin in human neoplasia. Cancer 31: 1–8, 1973.CrossRefGoogle Scholar
  2. 2.
    Blum RH: An overview of studies with adriamycin (NSC–123127) in the United States. Cancer Chemother Rep 6: 247–251, 1975.Google Scholar
  3. 3.
    Creagan ET, Hahn RG, Ahmann DL et al.: A clinical trial adriamycin (NSC 123127) in advanced sarcomas. Oncology 34: 90–91, 1977.PubMedCrossRefGoogle Scholar
  4. 4.
    Cruz AB Jr., Thames EA Jr., Aust. JB et al.: Combination chemotherapy for soft tissue sarcomas: A phase III study. J Surg Oncol 11: 313–323, 1979.PubMedCrossRefGoogle Scholar
  5. 5.
    Schoenfeld DA, Rosenbaum C, Horton J, et al.: A comparison of adriamycin versus vincristine and adriamycin and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 50: 2757–2762, 1982.PubMedCrossRefGoogle Scholar
  6. 6.
    O’Bryan RM, Baker LH, Gottlieb JE et al: Dose response evaluation of adriamycin in human neoplasia. Cancer 39: 1940–1948, 1977.PubMedCrossRefGoogle Scholar
  7. 7.
    Gottlieb JA, Benjamin RA, Baker LH et al.: Role of DTIC (NSC–45338) in the chemotherapy of sarcomas. Cancer Treat Rep 60: 199–203, 1976.PubMedGoogle Scholar
  8. 8.
    Luce JK, Thurman WG, Isaacs BL et al.: Clinical trials with the antitumor agent 5-(3,3- dimethyl-1-triazeno)imidazole-4-carboxamide (NSC–45388). Cancer Chemother Rep 54: 119–124, 1970.PubMedGoogle Scholar
  9. 9.
    Gottlieb JA, Baker LH, Quagliana JM et al.: Chemotherapy of sarcomas with a combination of adriamycin and dimethyl-triazenomidazole-carboxamide. Cancer 30: 1632–1638, 1972.PubMedCrossRefGoogle Scholar
  10. 10.
    Pinedo HM, Yendrik CPJ, Bramwell VHC et al.: Reevaluation of the CYVADIC regimen for metastatic soft tissue sarcoma. Proc AACR and ASCO (abstr) C–228, 1978.Google Scholar
  11. 11.
    Benjamin RS, Gottlieb JA, Baker LH et al: CYVADIC versus CYVADACT — a randomized trial of cyclophosphamide (CY), vincristine (V), and adriamycin (A) plus either dacarbazine (DIC), or actinomycin-D (DACT) in metastatic sarcomas. Proc Am Assoc Cancer Res Am Soc Clin Oncol, 17: 256, 1976.Google Scholar
  12. 12.
    Baker LH: Unpublished data.Google Scholar
  13. 13.
    Creagan ET, Hahn RG, Ahmann DL et al.: A comparative clinical trial evaluating the combination of adriamycin, DTIC, and vincristine, the combination of actinomycin-D, cyclophosphamide, and vincristine, and a single agent, methyl–CCNU, in advanced sarcomas. Cancer Treat Rep 60: 1385–1386, 1976.PubMedGoogle Scholar
  14. 14.
    Patten BM: Human Embryology. New York: McGraw–Hill, 1968.Google Scholar
  15. 15.
    Baker LH: Unpublished data.Google Scholar
  16. 15.
    Saiki JH: Unpublished data.Google Scholar
  17. 17.
    Gottlieb JA, Baker LH, Burgess MA et al.: Sarcoma chemotherapy. In: Cancer Chemotherapy Fundamental Concepts and Recent Advances, 19th Annual Clinical Conference in Cancer, 1974, MD. Anderson Hospital. Chicago: Year Book Medical Publishers, 1975.Google Scholar
  18. 18.
    Yap B, Baker LH, Sinkovics JG et al.: Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep 64: 93–98, 1980.PubMedGoogle Scholar
  19. 19.
    Blum RH, Carson JM, Wilson RE et al.: Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD). Cancer 46: 1722–1726, 1980.PubMedCrossRefGoogle Scholar
  20. 20.
    Rivkin SE, Gottlieb JA, Thigpen T et al.: Methyl CCNU and adriamycin for patients with metastatic sarcomas. A Southwest Oncology Group Study. Cancer 46: 446–451, 1980.PubMedCrossRefGoogle Scholar
  21. 21.
    Shiv MH, Magill GB, Hopfan S: Recent trends in treatment of soft tissue sarcomas–Appendix A.: In: Pathology of Soft Tumors, Hajdu SI (ed). Philadelphia: Lea & Febiger, 1979, pp 537–542.Google Scholar
  22. 22.
    Chang P, Wiernik PH: Combination chemotherapy with adriamycin and streptozotocin. Clin Pharmacol Ther 20: 605–610, 1976.PubMedGoogle Scholar
  23. 23.
    Lowenbraun S, Moffitt S, Smalley R et al.: Combination chemotherapy with adriamycin, cyclophosphamide and methotrexate in metastatic sarcomas. ASCO (abstr) 18: 286, 1977.Google Scholar
  24. 24.
    Kaufman JH, Catane R, Douglass HO Jr.: Combined adriamycin, vincristine, and methotrexate. NY State J Med, 742–743, 1977.Google Scholar
  25. 25.
    Golbey R, Li MC, Kaufman RF: Actinomycin in the treatment of soft part sarcomas. James Ewing Society Scientific Program (abstr ), 1968.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston/The Hague/Dordrecht/Lancaster 1983

Authors and Affiliations

  • Laurence H. Baker

There are no affiliations available

Personalised recommendations